Subclinical Cardiovascular Changes in NAFLD Patient (Predictive Value of Speckle Tracking Echocardiography )
NCT ID: NCT05790057
Last Updated: 2023-03-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60 participants
OBSERVATIONAL
2023-05-01
2025-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. the role of speckle tracking echocardiogram in detection of subclinical cardiovascular complication in NAFLD patients
2. the role of fibroscan in diagnosis of nonalcoholic fatty liver the participant will be examined by fibroscan and speckle tracking echocardiogram
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Frequency of Metabolic Dysfunction Associated Fatty Liver Disease in Patients With Acute Coronary Syndromes
NCT06456970
Assessment of Nonalcoholic Fatty Liver Disease in Diabetic and Prediabetic Patients Using Noninvasive Methods.
NCT04553796
Correlation Between Hepatic Fibrosis and Cardiovascular Risk Evaluated by Non-invasive Tests in Patients With NAFLD
NCT04774302
Screening for Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD) at Al-Rajhy Hospital Nutrition Clinic. Assiut, Egypt
NCT04861012
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
NCT05120557
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Fibroscan is an evidence based ,transient elastography instrument for noninvasive evaluation of liver steatosis and fibrosis There are various studies substantiating the use of fibroscan in NAFLD. In a study by Wong et al 246 patients underwent liver stiffness measurement by fibroscan , In a study carried out by Yoneda et al , AUROC for F1 , F2 , F3 , F4 fibrosis were 0.881, 0.876 , 0.914 and 0.997 , respectively. Musso et al showed that for nonalcoholic steatohepatitis (NASH) with advanced fibrosis, , sensitivity and specificity of fibroscan were 0.85, 0.90 , 0.97 and 0.94 . Another study from India by sarin et al showed similar efficacy of fibroscan in NAFLD in patients from Northern India4 Convincing evidence now substantiates a strong association between the presence and severity of ( NAFLD) and the risk of cardiomyopathy (mainly left ventricular dysfunction and hypertrophy , possibly leading to heart failure and arrhythmias 5 Speckle-tracking Echocardiography a non-invasive ultrasound imaging technique allows an objective and quantitative evaluation of global and regional myocardial function independently from the angle of insonation and cardiac translational movements based on an analysis of the spatial dislocation of speckles on routine 2 dimensional sonograms Because of its potential benefits in the measurement of left ventricular function along with other systolic and diastolic echocardiographic parameters of left ventricular function measurement this novel technique is used in this study to assess the relationship between NAFLD and subclinical myocardial dysfunction
All participants will be subjected to full history and examination including :
* Demographic data with special habits
* Underlying comorbidity (Diabetes mellitus , Hypertension , Cardiovascular disease
* Symptoms of NAFLD eg: fatigue , loss of appetite , weight loss , pale stool
* Symptoms of cardiac dysfunction including eg :
* heart failure ( shortness of breath , fatigue , swelling of the feet ankles ,legs , abdomen or neck veins )
* arrhythmia ( fluttering feelings in the chest \[palpitations} )
* heart attack ( chest pain or discomfort upper back or neck pain , indigestion , heartburn , nausea or vomiting , extreme fatigue ,upper body discomfort , dizziness and shortness of breath )
* Therapeutic history eg : drugs causing NAFLD ( corticosteroids , antidepressants , antipsychotics ) antihypertensive drugs , drugs to control Diabetes mellitus , Antiarrhythmic \& anti ischemic drugs
* EXAMINATION : \*vital signs ( blood pressure , pulse , temperature , respiratory rate ) \* dyslipidemic signs \* cardiovascular examination chest examination \* lower limb pulsation
* Laboratory investigation including:
1. liver function
2. lipid profile
3. HBA1C
4. Renal function
5. Erythrocyte sedimentation rate ( ESR) \& C - Reactive protein test ( CRP)
* Imaging including:
1. Fibroscan :
It is a special non-invasive ultrasound technology that measures liver stiffness (hardness) and fatty changes in the liver
2. Ultrasonography
3. Conventional Echocardiography :
It is an imaging technique that enables accurate assessment of cardiac structures and cardiac function
4. Speckle Tracking Echocardiography:
* Study Scores including:
1. ASCVD risk score (Atherosclerotic cardiovascular disease )
2. CHA2DS2-VASc score
* Sample size Sample size was calculated using Epi-Info7 based on prevalence of NAFLD and its subclinical cardiovascular abnormalities , the minimum patients required for this study is 60 patient
* statistical analysis : statistical analysis will be performed using SPSS statistics ( statistical package for the social sciences) version 20 (USA) , patient characteristics and outcomes will be reported using standard descriptive statistics : frequency (percentage ) for categorical variables and mean (SD) continuous variables .
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. All patients showing degree of fibrosis and steatosis
\-
Exclusion Criteria
2-patients known to have chronic liver disease
3-patients younger than 18 years old
4-patients with hepatocellular cancer
5-patients know to be alcoholic
6-patients with previous history of hypertension
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Omar Mohamed Magdy Eid
pricipal investigator , internal medicine resident
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
lobna m abdelwaheed, professor
Role: STUDY_DIRECTOR
supervisor of the research ( professor of internal medicine Assiut university
soheir m kasem, professor
Role: STUDY_DIRECTOR
supervisor of the research ( professor of internal medicine Assiut university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assiut university
Asyut, Assuit, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Kasper P, Martin A, Lang S, Kutting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021 Jul;110(7):921-937. doi: 10.1007/s00392-020-01709-7. Epub 2020 Jul 21.
Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, Yilmaz Y, Czernichow S, Zheng MH, Wong VW, Allison M, Tsochatzis E, Anstee QM, Sheridan DA, Eddowes PJ, Guha IN, Cobbold JF, Paradis V, Bedossa P, Miette V, Fournier-Poizat C, Sandrin L, Harrison SA. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020 Apr;5(4):362-373. doi: 10.1016/S2468-1253(19)30383-8. Epub 2020 Feb 3.
Oeda S, Tanaka K, Oshima A, Matsumoto Y, Sueoka E, Takahashi H. Diagnostic Accuracy of FibroScan and Factors Affecting Measurements. Diagnostics (Basel). 2020 Nov 12;10(11):940. doi: 10.3390/diagnostics10110940.
Pathik P, Ravindra S, Ajay C, Prasad B, Jatin P, Prabha S. Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from Western India. Ann Gastroenterol. 2015 Apr-Jun;28(2):281-286.
Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018 Jul;15(7):425-439. doi: 10.1038/s41575-018-0010-0.
Zamirian M MD, Samiee E MD, Moaref A MD, Abtahi F MD, Tahamtan M MD. Assessment of Subclinical Myocardial Changes in Non-Alcoholic Fatty Liver Disease: A Case-Control Study Using Speckle Tracking Echocardiography. Iran J Med Sci. 2018 Sep;43(5):466-472.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
cardiac complication in NAFLD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.